Skip to main content
Premium Trial:

Request an Annual Quote

LabGenomics Acquires QDx Pathology

NEW YORK – LabGenomics USA, a subsidiary of South Korean-based diagnostics firm LabGenomics, said Tuesday that it has acquired QDx Pathology for an undisclosed amount.

LabGenomics said that the acquisition of the molecular and diagnostic pathology firm is part of its plans to expand its market reach in North America.

"We are thrilled to be joining forces with LabGenomics and look forward to the opportunities this acquisition will bring," QDx CEO Tim Rich said in a statement. "Together, we can leverage our strengths and provide a broader range of diagnostic tests and services to our customers."

"We intend to enter the U.S. diagnostic market at an innovative and reasonable price through the technology and know-how of NGS-based molecular diagnosis provided by LabGenomics," LabGenomics USA CEO Junghee Cho said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.